FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Lab Group Seeks Congress Help on LDT Rule

The Association for Diagnostics and Laboratory Medicine raises significant concerns regarding the recent FDA final rule on laboratory-developed tests,...

latest-news-card-1
Human Drugs

Traveres Filspari Converted to Full Approval

FDA grants Travere Therapeutics full approval for Filspari (sparsentan) for slowing kidney function decline in adults with primary immunoglobulin A ne...

latest-news-card-1
Federal Register

Info Collection on Drug Supply Security

Federal Register notice: FDA seeks comments on an information collection revision entitled Pharmaceutical Distribution Supply Chain; Drug Supply Chain...

latest-news-card-1
Federal Register

Guide on Device Patient Preference Information

Federal Register notice: FDA makes available a draft guidance entitled Incorporating Voluntary Patient Preference Information over the Total Product L...

latest-news-card-1
Federal Register

Panel to Review Stealth Bio Barth Syndrome NDA

Federal Register notice: FDA announces a 10/10 Cardiovascular and Renal Drugs Advisory Committee meeting to review a Stealth BioTherapeutics NDA for e...

latest-news-card-1
Human Drugs

GSK Reports Trial Results of Nucala in COPD

GSK says data from its Phase 3 MATINEE clinical trial evaluating chronic obstructive pulmonary disease drug Nucala (mepolizumab) met its primary endpo...

Medical Devices

Odin Medical AI Colon Polyp Detector

FDA clears an Odin Medical (an Olympus subsidiary) 510(k) for what it describes as the first cloud-based artificial intelligence technology to assist ...

latest-news-card-1
Human Drugs

Eye Product Manufacturer Hit with Warning Letter

FDA issues Regenerative Processing Plant a Warning Letter based on a 2023 inspection of the firms Palm Harbor, FL, manufacturing plant that found sign...

latest-news-card-1
Human Drugs

Taenaka Kogyo Inspection Cites 4 Observations

An April inspection of Japans Taenaka Kogyo ends in a four-observation Form FDA-483 that cites significant GMP violations.

latest-news-card-1
Biologics

Biocon Biologics Gets 10-item FDA-483

FDA posts a Form FDA-483 issued to Biocon Biologics at the end of a July inspection at the firms Bengaluru, India manufacturing facility.